In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising...
Read MorePimavanserin improves depression in patients with Parkinson’s disease
In a nutshell This study investigated the effectiveness of pimavanserin (Nuplazid) in the treatment of depression in patients with Parkinson’s disease (PD). Researchers suggested that this treatment improves depression in patients with PD. Some background PD affects certain brain cells which can result in physical symptoms such as...
Read MoreBlinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia
In a nutshell This study aimed to evaluate the use of blinatumomab Blincyto; B) or inotuzumab ozogamicin (Besponsa; IO) as a bridge to stem cell transplant for patients with relapsed or refractory (unresponsive) B-cell acute lymphocytic leukemia (B-ALL). This study concluded that both treatments are safe and effective as a...
Read MoreEvaluating osimertinib for EGFR positive non-small-cell lung cancer that was surgically removed.
In a nutshell This trial was carried out to assess the effectiveness and safety of osimertinib (Tagrisso) after surgery for EGFR-positive advanced non-small cell lung cancer (NSCLC). The trial found that this treatment improved the outcomes of patients with stage IB to IIIA EGFR-positive NSCLC that was surgically removed. Some...
Read MoreComparing the outcomes of carfilzomib once-weekly vs twice-weely in patients with relapsed/refractory multiple myeloma
In a nutshell The study compared outcomes of once-weekly (OW) versus twice-weekly (TW) carfilzomib (Kyprolis) plus dexamethasone (Decadron) in Japanese patients with relapsed/refractory (RR) multiple myeloma (MM). The authors found that the OW dosage improved overall response rate (ORR) compared to TW in such patients. Some background RR-MM...
Read MoreIncreasing solifenacin dose is effective and safe for male patients with unresponsive overactive bladder
In a nutshell This study investigated the effectiveness and safety of increasing the dose of solifenacin (Vesicare) treatment in male patients with overactive bladder (OAB) that does not respond to low-dose treatment. Researchers suggested that increasing the dose of solifenacin is safe and improves the outcomes of these patients. Some...
Read MoreLong term outcomes of dasatinib as a second line treatment in patients with chronic myeloid leukemia
In a nutshell This study aimed to investigate the long-term outcomes of dasatinib treatment for patients with chronic myeloid leukemia who were resistant or intolerant to imatinib in daily clinical practice. This study concluded that dasatinib is safe and effective in these patients. Some background...
Read MoreLonger survival without progression in patients with NSCLC with nivolumab plus chemotherapy before surgery
In a nutshell This study investigated the antitumor activity, safety, and survival after nivolumab (Opdivo) and chemotherapy before surgery for patients with stage IIIA non-small-cell lung cancer (NSCLC). The study showed a high rate of survival without cancer worsening among these patients. Some background NSCLC amounts to over 80% of...
Read MoreIs R-FND and ibritumomab tiuxetan an appropriate treatment for untreated high-risk follicular lymphoma?
In a nutshell This trial was carried out to assess the effectiveness R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) followed by ibritumomab tiuxetan (YIT; Zevalin) radioimmunotherapy (RIT), and rituximab maintenance therapy in patients with untreated high-risk follicular...
Read MorePembrolizumab followed by AVD treatment in newly diagnosed advanced classical Hodgkin lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of pembrolizumab (Keytruda) followed by AVD (doxorubicin, vinblastine, and dacarbazine) treatment in patients with high-risk classical Hodgkin lymphoma. This study concluded that this treatment was safe and effective in these patients. Some...
Read MoreLonger-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer
In a nutshell This study evaluated longer-term survival rates and the safety of olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC). It found that treatment with olaparib led to significantly longer survival, especially in men with gene alterations. Some background CRPC is an especially aggressive...
Read MoreEvaluating the timing of chemotherapy plus bevacizumab for patients with colorectal cancer and liver metastasis
In a nutshell This study investigated whether chemotherapy plus bevacizumab (Avastin) before and after or after surgery improves the survival of patients with colorectal cancer (CRC) and operable liver metastasis (LM; cancer spread to the liver). Researchers suggested that chemotherapy and bevacizumab before and after...
Read More